Toxicité des nouveaux médicaments : incidence et prise en charge (notice n° 659552)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01642cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121191927.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Sibon, David |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Toxicité des nouveaux médicaments : incidence et prise en charge |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 87 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | De nouveaux médicaments, différents de la chimiothérapie classique, sont disponibles en France pour le traitement des lymphomes T périphériques (LTP, à l’exclusion des lymphomes T cutanés) : il s’agit du brentuximab vedotin et des inhibiteurs d’histone désacétylase. Ces nouveaux traitements ont des toxicités spécifiques nécessitant des adaptations de doses et/ou un espacement des administrations en fonction du grade de toxicité. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | New drugs, different from conventional chemotherapy, are available in France for the treatment of peripheral T-cell lymphomas (PTCL, excluding cutaneous T-cell lymphomas): these are brentuximab vedotin and histone deacetylase inhibitors. These new treatments have specific toxicities requiring dose adjustments and/or dose delay depending on the grade of toxicity. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | brentuximab vedotin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | toxicité |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Lymphome T périphérique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | inhibiteurs d’histone désacétylase |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | histone deacetylase inhibitors |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Peripheral T-cell lymphomas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | brentuximab vedotin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | toxicity |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 26 | N° Supp 6 | 2020-12-15 | p. 43-46 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2020-HS6-page-43?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2020-HS6-page-43?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux